

PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Title
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	Abstract
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	Introduction
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	Eligibility criteria
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	Search
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Search
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Selection/Study Characteristics
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	Data abstraction
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	Quantitative data synthesis
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	Quantitative data synthesis
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Quantitative data synthesis
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Quantitative data synthesis



PRISMA 2009 Checklist

Page 1 of 2

RESULTS Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective data synthesis data synthesis and continuous managements of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective data synthesis data synthesis of pescential managements of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions are each stage, ideally with a flow diagram. Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Quantitative Summary (Meta-analysis of results of individual studies intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Quantitative Summary (Meta-analysis of each study) and provide the citations of the publication bias Additional analysis 22 Present results of any assessment of risk of bias across studies (see Item 15). DISCUSSION 24 Summarize the main findings including the strength of evidence for each main outcome, consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).					
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, industries data synthesis of sudditional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, industries with the synthesis of study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) Qualitative summary (Meta-analysis) Results of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Quantitative summary (Meta-analysis) Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Quantitative summary (Meta-analysis) Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Quantitative summary (Meta-analysis) Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Assessment publication bias Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression (see Item 16)). Quantitative summary (Meta-analysis) DISCUSSION 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance Discussion (dentified research, reporting bias). Conclusions Provide a general interpretation of the results in the context of other evidence, and implications for future Conclusions Conclusions Conclusions Conclusions Conclusions Conclusions Conclusions Conclusions Con	Section/topic	#	Checklist item	Reported on page #	
RESULTS Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) Qualitative Summary and provide the citations. Risk of bias within studies Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Quantitative Summary (Meta-analysis of results of individual studies of results of individual studies of results of individual studies of each study and, if available, any outcome level assessment (see item 12). Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals, ideally with a forest plot. Warmary (Meta-analysis of results) Present results of each meta-analysis done, including confidence intervals and measures of consistency. Quantitative Summary (Meta-analysis of each study) of present results of any assessment of risk of bias across studies (see Item 15). Assessment of Publication bias of each studies (see Item 15). Present results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). Quantitative Summary of evidence of evidence of reach main outcome; consider their relevance of tokey groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discussi limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future of conclusions research.	Risk of bias across studies	15		Quantitative data synthesis	
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) Summary (Meta-analysis and provide the citations. Risk of bias within studies 20 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Quantitative Summary (Meta-analysis Summary (Meta-analysis Summary (Meta-analysis) Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Quantitative Summary (Meta-analysis Summary (Meta-analysis) Synthesis of results 22 Present results of any assessment of risk of bias across studies (see Item 15). Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). PISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Limitations 26 Provide a general interpretation of the results in the context of other evidence, and implications for future Conclusions research.	Additional analyses	16		Quantitative data synthesis	
at each stage, ideally with a flow diagram. Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Quantitative Summary (Meta-analysis untervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Quantitative Summary (Meta-analysis Synthesis of results 22 Present results of any assessment of risk of bias across studies (see Item 15). Assessment of Publication bias 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Conclusions 26 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future conclusions	RESULTS				
Risk of bias within studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each summary (Meta-analysis Or each study: (a) simple summary data for each summary (Meta-analysis or intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Quantitative Summary (Meta-analysis)	Study selection	17		Search results	
Results of individual studies Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each guantitative. Summary (Meta-analysis Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Quantitative summary (Meta-analysis Risk of bias across studies) 22 Present results of any assessment of risk of bias across studies (see Item 15). Assessment of Publication bias Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). Quantitative Summary (Meta-analysis Obscussion) DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.	Study characteristics	18			
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Summary (Meta-analysis Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Quantitative Summary (Meta-analysis Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Assessment of Publication bias Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). Quantitative Summary of evidence DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.	Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).		
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of limitations identified research, reporting bias). Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future Conclusions	Results of individual studies	20			
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). Quantitative Summary (Meta-analysis) DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of limitations) Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future Conclusions	Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.		
DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future Conclusions	Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).		
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of limitations 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. Conclusions	Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).		
to key groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of limitations Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. Conclusions	DISCUSSION				
identified research, reporting bias). Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. Conclusions	Summary of evidence	24		Discussion	
research.	Limitations	25		Strengths and limitations	
FUNDING	Conclusions	26		Conclusions	
	FUNDING				



PRISMA 2009 Checklist

Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	
---------	----	--------------------------------------------------------------------------------------------------------------------------------------------	--

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2